Not Signed In -
Depression |
Depression/depressive Disorders |
Clinical Trial: Preventing Depression in Patients with Macular Degeneration
This study is currently recruiting patients.
|
Purpose
The purpose of this study is to evaluate the efficacy of a brief, standardized cognitive psychotherapy called Problem Solving Treatment (PST) to prevent depression in elderly patients with age-related macular degeneration (AMD).
| Condition | Treatment or Intervention |
|---|---|
| Depression Macular Degeneration | Behavior: Problem Solving Treatment |
MedlinePlus related topics: Depression; Macular Degeneration
Study Type: Interventional
Study Design: Prevention, Randomized, Single Blind, Active Control, Parallel Assignment, Efficacy Study
Official Title: Preventing Depression in Macular Degeneration
Expected Total Enrollment: 230
Study start: February 2001; Expected completion: January 2005
AMD is the most common cause of blindness in older adults. The disease limits the ability to read, see familiar faces, and walk independently. Almost 2 million persons (about 5 percent of the U.S. population over age 65) are now affected, and this number will triple by the year 2020. This study will target patients with neovascular AMD (NV-AMD), a form of AMD which can lead to sudden vision loss, substantial disability, and depression. Because depression is itself disabling and not likely to be recognized nor treated by ophthalmologists, preventing depression in people with NV-AMD is important.
Patients are randomly assigned to either PST or a usual care control condition. The primary outcome measure is a DSM-IV diagnosis of depression. Patients are evaluated at baseline, Month 2 (immediately post-intervention), Month 6 (for the primary efficacy analysis), and Month 12 (to evaluate sustained effects). The study will also assess the impact of PST on levels of disability and vision-related quality of life.
Eligibility
Ages Eligible for Study: 65 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion criteria:
- Bilateral macular degeneration
- Visual acuity of 20/40 or worse in better eye
- Residence within 40 miles of Wills Eye Hospital in Philadelphia, PA
Location and Contact Information
Pennsylvania
Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States; Recruiting
Barry W Rovner, MD 215-503-1254 Barry.Rovner @jefferson.edu
Barry W Rovner, MD, Principal Investigator
More Information
Publications
Rovner BW, Casten RJ. Activity loss and depression in age-related macular degeneration. Am J Geriatr Psychiatry. 2002 May-Jun;10(3):305-10.
Rovner BW, Casten RJ. Neuroticism predicts depression and disability in age-related macular degeneration. J Am Geriatr Soc. 2001 Aug;49(8):1097-100.
Rovner BW, Ganguli M. Depression and disability associated with impaired vision: the MoVies Project. J Am Geriatr Soc. 1998 May;46(5):617-9.
Rovner BW, Casten RJ, Tasman WS. Effect of depression on vision function in age-related macular degeneration. Arch Ophthalmol. 2002 Aug; 120(8): 1041-4.
Tasman, W., & Rovner, B. W. (in press). Age related macular degeneration: reating the whole person. Archives in Ophthalmology
Casten, R. J., Rovner, B. W., & Tasmas, W. (in press). Age related macular degeneration and depression: a review of recent research. Current Opinions in Ophthalmololgy.
Casten, R. J., & Rovner, B. W. The role of psychological characteristics in the use and perceived importance of low vision aids. Submitted to the Journal of Vision Impairment and Blindness
Rovner, B. W., & Casten, R. J. Stability of Visual Acuity Measurement in Depression. Submitted to the Archives of Ophthalmology.
Record last reviewed: March 2005
Last Updated: March 2, 2005
Record first received: July 24, 2002
ClinicalTrials.gov Identifier: NCT00042211
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
